{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:05:34Z","timestamp":1779163534349,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ahj.2008.09.006","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T03:24:32Z","timestamp":1227669872000},"page":"1154.e1-1154.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide\/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension"],"prefix":"10.1016","volume":"156","author":[{"given":"Claudio","family":"Napoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Ignarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"de Nigris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Williams-Ignarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Libardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Sommese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Fiorito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco P.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cacciatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2008.09.006_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00129784-200707010-00002","article-title":"Defining the role of zofenopril in the management of hypertension and ischemic heart disorders","volume":"7","author":"Ambrosioni","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ahj.2008.09.006_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/156726905774641190","article-title":"New challenges for ACE-inhibitors in vascular diseases","volume":"2","author":"Napoli","year":"2005","journal-title":"Drug Design Rev"},{"key":"10.1016\/j.ahj.2008.09.006_bib3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2174\/0929867054367257","article-title":"New trends in anti-atherosclerotic agents","volume":"12","author":"Napoli","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ahj.2008.09.006_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjhyper.2006.09.020","article-title":"Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients","volume":"20","author":"Pasini","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2008.09.006_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.2526370","article-title":"Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury","volume":"245","author":"Powell","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ahj.2008.09.006_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.HYP.24.6.671","article-title":"Role of the renin-angiotensin system in neointima formation after injury in rabbits","volume":"24","author":"Janiak","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2008.09.006_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(94)90080-9","article-title":"Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture","volume":"106","author":"Fennessy","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2008.09.006_bib8","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0306-3623(99)00043-9","article-title":"Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits","volume":"33","author":"Napoli","year":"1999","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.ahj.2008.09.006_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/01.HYP.15.3.327","article-title":"Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit","volume":"15","author":"Chobanian","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2008.09.006_bib11","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00005344-199000005-00010","article-title":"Effects of captopril on atherosclerosis in cynomolgus monkeys","volume":"15","author":"Aberg","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2008.09.006_bib12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/00005344-199804000-00011","article-title":"Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice","volume":"31","author":"Hayek","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2008.09.006_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-5273(01)00542-3","article-title":"Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice","volume":"81","author":"de Nigris","year":"2001","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2008.09.006_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/107424840100600209","article-title":"Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function","volume":"6","author":"Sun","year":"2001","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2008.09.006_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.ATV.13.8.1125","article-title":"ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries","volume":"13","author":"Charpiot","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.ahj.2008.09.006_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","article-title":"Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice","volume":"106","author":"Candido","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9150(94)90037-X","article-title":"Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids","volume":"108","author":"Kowala","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2008.09.006_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0008-6363(99)00239-4","article-title":"The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice","volume":"44","author":"Hayek","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2008.09.006_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(98)00309-8","article-title":"Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits","volume":"143","author":"Li","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2008.09.006_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00005344-200001000-00008","article-title":"Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin","volume":"35","author":"Keidar","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2008.09.006_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0021-9150(01)00621-9","article-title":"Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis","volume":"161","author":"Hayek","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2008.09.006_bib22","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/01.CIR.89.3.952","article-title":"Plasma angiotensin-converting enzyme activity and carotid wall thickening","volume":"89","author":"Bonithon-Kopp","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0735-1097(00)00736-1","article-title":"Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease: PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril","volume":"36","author":"MacMahon","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2008.09.006_bib24","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","article-title":"Long-term effects of cholesterol lowering, and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin\/enalapril coronary atherosclerosis trial","volume":"102","author":"Teo","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1161\/01.STR.0000155731.92786.e9","article-title":"Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria","volume":"36","author":"Asselbergs","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib26","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS\u2014a randomized double-blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib27","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.CIR.103.7.919","article-title":"Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE)","volume":"103","author":"Lonn","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib28","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","article-title":"the role of the renin-angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2008.09.006_bib29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archinte.163.10.1155","article-title":"Renin-angiotensin system and atherothrombotic disease: from genes to treatment","volume":"163","author":"Jacoby","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2003.10.002","article-title":"The effect of angiotensin converting enzyme inhibition on endothelial function and oxidant stress","volume":"482","author":"Scribner","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ahj.2008.09.006_bib31","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ahj.2004.03.025","article-title":"Sulfhydryl ACE inhibition induces a sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension","volume":"148","author":"Napoli","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2008.09.006_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/147323000503300103","article-title":"Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril","volume":"33","author":"Evangelista","year":"2005","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ahj.2008.09.006_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0895-7061(02)02995-3","article-title":"Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species","volume":"15","author":"Cominacini","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2008.09.006_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2796.1994.tb00847.x","article-title":"Carotid artery intima-media thickness as an indicator of generalized atherosclerosis","volume":"263","author":"Grobbee","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","article-title":"Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group","volume":"340","author":"O'Leary","year":"1999","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib36","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/CIRCULATIONAHA.105.570358","article-title":"Rethinking primary prevention of atherosclerosis-related diseases","volume":"114","author":"Napoli","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2796.1996.79878000.x","article-title":"Relations between vasoactive hormonal factors and left ventricular diastolic function in normotensive and hypertensive uremics","volume":"240","author":"Napoli","year":"1996","journal-title":"J Intern Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/01.ATV.12.2.261","article-title":"Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurements of arterial wall thickness and plaque size","volume":"12","author":"Persson","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.ahj.2008.09.006_bib39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.STR.26.3.386","article-title":"Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"26","author":"Burke","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1161\/01.STR.28.2.348","article-title":"Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease: the Edinburgh Artery Study","volume":"28","author":"Allan","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib42","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.STR.0000227223.90239.13","article-title":"Carotid intima-media thickness and antihypertensive treatment. A meta-analysis of randomized controlled trials","volume":"37","author":"Wang","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib43","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/01.STR.32.7.1539","article-title":"Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non\u2013insulin-dependent diabetes mellitus","volume":"32","author":"Hosomi","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/01.STR.27.3.480","article-title":"Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses","volume":"27","author":"Espeland","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2008.09.006_bib45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198705283162204","article-title":"Compensatory enlargement of human atherosclerotic coronary arteries","volume":"316","author":"Glagov","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9149(98)00780-2","article-title":"for the QUIET Investigators (Quinapril Ischemic Event Trial). Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet","volume":"83","author":"Cashin-Hemphill","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2008.09.006_bib47","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1161\/01.CIR.98.25.2842","article-title":"Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure","volume":"98","author":"Hornig","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2008.09.006_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.hjh.0000191244.91314.9d","article-title":"Blockade of renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes","volume":"24","author":"Burnier","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2008.09.006_bib49","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2008.09.006_bib50","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.09.006_bib51","first-page":"1115","article-title":"GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2008.09.006_bib52","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/0006-2952(90)90250-O","article-title":"Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells","volume":"40","author":"Mak","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ahj.2008.09.006_bib53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","article-title":"The effect of angiotensin-converting\u2013enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction","volume":"332","author":"Ambrosioni","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2008.09.006_bib54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0895-7061(99)00042-4","article-title":"Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation","volume":"12","author":"Borghi","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2008.09.006_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1067\/mhj.2003.24","article-title":"Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-Term Evaluation-2 (SMILE-2) study","volume":"145","author":"Borghi","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2008.09.006_bib56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/niox.2001.0337","article-title":"Nitric oxide and atherosclerosis","volume":"5","author":"Napoli","year":"2001","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.ahj.2008.09.006_bib57","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2006.03.022","article-title":"Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study","volume":"191","author":"Furuki","year":"2007","journal-title":"Atherosclerosis"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870308007916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870308007916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:36:43Z","timestamp":1757569003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870308007916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0002870308007916"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2008.09.006","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide\/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2008.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}